An Accord for a Healthier World
The Accord aims to provide access to Pfizer’s full portfolio of patented and off-patent medicines and vaccines for which Pfizer holds global rights on a not-for-profit basis to 1.2 billion people living in 45 lower-income countries around the world.
Objectives
- Providing all Pfizer’s patent-protected medicines and vaccines available in the US or European Union on a not-for-profit basis to 45 low- and lower-middle-income countries around the world.
- Providing all future Pfizer medicines and vaccines.
- Fostering partnerships that will collaborate to identify and address barriers that limit access beyond supply, like diagnosis, education, infrastructure, storage and more.
An Accord for a Healthier World is a first-of-its-kind initiative to enable sustained, equitable access to high-quality, safe, and effective medicines and vaccines with the potential to improve the health of 1.2 billion people living in 45 lower-income countries. Under the Accord, Pfizer has committed to offer the full portfolio for which the company holds global rights on a not-for-profit basis to these countries. By doing so, the Accord aims to provide prevention and treatment options for those impacted by deadly infectious diseases, as well as heart disease, certain cancers, rare and inflammatory diseases, and more.
Alongside governments and multi-sector leaders, the Accord will focus on co-creating solutions for faster, more efficient supply pathways for medicines and vaccines as well as strengthening the resources, capabilities, and platforms that can enable quick, yet sustainable access to them, including technical expertise, training, diagnostic capacity, innovative financing, and beyond.
Results and milestones
- In September 2022, Rwanda became the first country to receive a delivery of Pfizer patent-protected medicines and vaccines through the Accord, including nine products to help treat or prevent life-threatening infectious and inflammatory diseases and certain cancers. Together, the Rwandan Ministry of Health and Pfizer are working to provide professional healthcare education and training to support Rwandan medical specialists.
- In November 2022, Pfizer deployed its first Global Health Team to Rwanda to help identify opportunities for long-term supply chain optimization.
- The Accord was launched during the World Economic Forum Davos meeting in May 2022.
- Rwanda, Ghana, Malawi, Senegal, and Uganda are the first five countries who have principally agreed to join the Accord. Partners will work to identify opportunities to support improved diagnosis, healthcare professional education, and training, along with supply chain management and other infrastructure enhancements to ensure all medicines and vaccines can reach those in need. Health officials in these countries will help identify and resolve hurdles beyond supply to inform the roll out in all 45 LICs and help speed sustainable access.
- In September 2022, the first product under the Accord arrived in Rwanda.
Geographic Reach
- Africa
- Americas
- Eastern Mediterranean
- Europe
- South-East Asia
- Western Pacific
Disease Area
- Infectious and Parasitic Disease
- Women’s and Child Health
- Non-communicable diseases
Geographic Reach
Africa
- Benin
- Burkina Faso
- Burundi
- Central African Republic
- Chad
- Comoros
- Congo
- Eritrea
- Ethiopia
- Gambia
- Ghana
- Guinea
- Guinea-Bissau
- Kenya
- Liberia
- Madagascar
- Malawi
- Mali
- Mauritania
- Mozambique
- Niger
- Rwanda
- Senegal
- Sierra Leone
- South Sudan
- Togo
- Uganda
- United Republic of Tanzania
- Zambia
- Zimbabwe
Americas
- Haiti
Eastern Mediterranean
- Afghanistan
- Somalia
- Sudan
- Syrian Arab Republic
- Yemen
Europe
- Kyrgyzstan
- Tajikistan
South-East Asia
- Bangladesh
- Democratic People's Republic of Korea
- Myanmar
- Nepal
Western Pacific
- Cambodia
- Lao People's Democratic Republic
- Republic of Korea
- Solomon Islands